Advertisement

Topics

ASIT biotech Announces the Approval by the Regulatory Authorities of a Follow-up Study of the Phase I/IIa Clinical Trial with its hdm-ASIT+™ Product Candidate for House Dust Mite Rhinitis

11:47 EDT 16 Aug 2017 | FinanzNachrichten

A subset of patients treated during the Phase I/IIa clinical trial with its hdm-ASIT+™ product candidate for house dust mite rhinitis will undergo a complementary medical visit to assess potential...

Original Article: ASIT biotech Announces the Approval by the Regulatory Authorities of a Follow-up Study of the Phase I/IIa Clinical Trial with its hdm-ASIT+™ Product Candidate for House Dust Mite Rhinitis

NEXT ARTICLE

More From BioPortfolio on "ASIT biotech Announces the Approval by the Regulatory Authorities of a Follow-up Study of the Phase I/IIa Clinical Trial with its hdm-ASIT+™ Product Candidate for House Dust Mite Rhinitis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...